SG11202109982YA - Drug and method for treating or preventing diabetes complications using same drug - Google Patents
Drug and method for treating or preventing diabetes complications using same drugInfo
- Publication number
- SG11202109982YA SG11202109982YA SG11202109982YA SG11202109982YA SG 11202109982Y A SG11202109982Y A SG 11202109982YA SG 11202109982Y A SG11202109982Y A SG 11202109982YA SG 11202109982Y A SG11202109982Y A SG 11202109982YA
- Authority
- SG
- Singapore
- Prior art keywords
- drug
- treating
- preventing diabetes
- diabetes complications
- same
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019044670 | 2019-03-12 | ||
| PCT/JP2020/010967 WO2020184691A1 (ja) | 2019-03-12 | 2020-03-12 | 薬剤及び該薬剤を用いて糖尿病合併症を治療又は予防する方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202109982YA true SG11202109982YA (en) | 2021-10-28 |
Family
ID=72426033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202109982Y SG11202109982YA (en) | 2019-03-12 | 2020-03-12 | Drug and method for treating or preventing diabetes complications using same drug |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220218664A1 (de) |
| EP (1) | EP3939659A4 (de) |
| JP (1) | JPWO2020184691A1 (de) |
| KR (1) | KR20220009371A (de) |
| CN (1) | CN114126711A (de) |
| AU (1) | AU2020238177A1 (de) |
| BR (1) | BR112021018084A8 (de) |
| CA (1) | CA3133204A1 (de) |
| CL (1) | CL2021002373A1 (de) |
| EA (1) | EA202192483A1 (de) |
| IL (1) | IL286289A (de) |
| MX (1) | MX2021011007A (de) |
| PE (1) | PE20220333A1 (de) |
| SG (1) | SG11202109982YA (de) |
| WO (1) | WO2020184691A1 (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220040294A (ko) * | 2020-09-23 | 2022-03-30 | 씨엔지바이오 주식회사 | 6-메톡시-2-펜에틸이소인돌린-1-온 유도체 및 이를 포함하는 신경질환의 치료용 조성물 |
| EP4293028A1 (de) * | 2021-02-10 | 2023-12-20 | Shanghai Senhui Medicine Co., Ltd. | Smtp-7 derivat und dessen verwendung |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05176782A (ja) * | 1992-01-08 | 1993-07-20 | Taisho Pharmaceut Co Ltd | Ｎｇｆ作用増強因子 |
| JP4313049B2 (ja) | 2003-01-23 | 2009-08-12 | 株式会社ティーティーシー | 血管新生関連疾患の予防又は治療用医薬組成物 |
| JP2004224737A (ja) | 2003-01-23 | 2004-08-12 | Ttc:Kk | 新規トリプレニルフェノール化合物 |
| US20090270476A1 (en) | 2005-10-06 | 2009-10-29 | Keiji Hasumi | Pharmaceutical composition for treatment or prevention of nephritis and manufacturing method thereof |
| EP2000540B1 (de) | 2006-03-27 | 2014-05-14 | Tokyo University of Agriculture and Technology Tlo Co., Ltd. | Triprenylphenolverbindung, verfahren zur herstellung einer triprenylphenolverbindung und thrombolyseverstärker |
| WO2010110026A1 (ja) * | 2009-03-25 | 2010-09-30 | 国立大学法人東京農工大学 | メタボリックシンドローム、肥満、高血糖症、高脂血症および／又は脂肪肝のための医薬組成物 |
| USRE47684E1 (en) * | 2009-07-06 | 2019-11-05 | Tms Co., Ltd. | Cytoprotective agent |
| WO2011125930A1 (ja) * | 2010-04-02 | 2011-10-13 | 日本製薬株式会社 | 炎症性腸疾患又は自己免疫性の末梢神経障害の予防又は治療剤 |
| JP2019044670A (ja) | 2017-08-31 | 2019-03-22 | スズキ株式会社 | 内燃機関の排出ガス浄化システム |
-
2020
- 2020-03-12 EP EP20771088.0A patent/EP3939659A4/de not_active Withdrawn
- 2020-03-12 CA CA3133204A patent/CA3133204A1/en active Pending
- 2020-03-12 EA EA202192483A patent/EA202192483A1/ru unknown
- 2020-03-12 PE PE2021001508A patent/PE20220333A1/es unknown
- 2020-03-12 CN CN202080035808.7A patent/CN114126711A/zh active Pending
- 2020-03-12 MX MX2021011007A patent/MX2021011007A/es unknown
- 2020-03-12 WO PCT/JP2020/010967 patent/WO2020184691A1/ja unknown
- 2020-03-12 AU AU2020238177A patent/AU2020238177A1/en not_active Abandoned
- 2020-03-12 US US17/438,801 patent/US20220218664A1/en active Pending
- 2020-03-12 BR BR112021018084A patent/BR112021018084A8/pt unknown
- 2020-03-12 SG SG11202109982Y patent/SG11202109982YA/en unknown
- 2020-03-12 KR KR1020217032312A patent/KR20220009371A/ko unknown
- 2020-03-12 JP JP2021505150A patent/JPWO2020184691A1/ja not_active Withdrawn
-
2021
- 2021-09-10 CL CL2021002373A patent/CL2021002373A1/es unknown
- 2021-09-12 IL IL286289A patent/IL286289A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020238177A1 (en) | 2021-11-04 |
| IL286289A (en) | 2021-10-31 |
| BR112021018084A8 (pt) | 2022-10-04 |
| US20220218664A1 (en) | 2022-07-14 |
| EP3939659A1 (de) | 2022-01-19 |
| KR20220009371A (ko) | 2022-01-24 |
| PE20220333A1 (es) | 2022-03-14 |
| EP3939659A4 (de) | 2022-12-21 |
| CA3133204A1 (en) | 2020-09-17 |
| MX2021011007A (es) | 2022-03-11 |
| CL2021002373A1 (es) | 2022-06-17 |
| EA202192483A1 (ru) | 2021-12-24 |
| WO2020184691A1 (ja) | 2020-09-17 |
| BR112021018084A2 (de) | 2021-12-21 |
| JPWO2020184691A1 (de) | 2020-09-17 |
| CN114126711A (zh) | 2022-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3817733A4 (de) | Zusammensetzung und verfahren zur behandlung von schmerzen | |
| SG10201908697XA (en) | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease | |
| EP3395353A4 (de) | Verfahren zur prävention oder behandlung von diabetes-mellitus- nervenverletzungen und verwandten erkrankungen | |
| IL286289A (en) | A drug and a method for treating or preventing diabetes complications using the same drug | |
| EP3858353A4 (de) | Pharmazeutische zusammensetzung zur vorbeugung und behandlung von nitm und ihre pharmazeutische verwendung | |
| EP3556379A4 (de) | Verfahren und wirkstoff zur prävention und behandlung von fettleibigkeit | |
| EP3866736A4 (de) | Verfahren und vorrichtungen zur behandlung von schlafapnoe | |
| EP3745967A4 (de) | Vorrichtungen und verfahren zur behandlung verstopfter blutgefässe | |
| EP4158645A4 (de) | Digitale vorrichtung und anwendung zur behandlung von myopie | |
| EP3705156A4 (de) | Vorrichtung und verfahren zur intrazerebralen arzneimittelinjektion | |
| EP3609522A4 (de) | Verfahren und verbindungen zur behandlung von diabetes | |
| EP3804759A4 (de) | Verfahren zur behandlung von schuppen oder vorbeugung von gnase-1-folgeerkrankungen | |
| EP3725326A4 (de) | Verfahren und arzneimittel zur vorbeugung oder behandlung von osteoarthritis | |
| IL284565A (en) | A system for administering avalopertide transdermally and a method of use | |
| EP3826980A4 (de) | Zusammensetzung und verfahren zur behandlung von harnstoff | |
| EP3677267A4 (de) | Pharmazeutische zusammensetzung zur tumorbehandlung oder -vorbeugung, verfahren und verwendung davon | |
| IL285828A (en) | Compounds for the treatment and prevention of complications associated with extracellular neutrophil traps | |
| EP3999077A4 (de) | Zusammensetzung und verfahren zur behandlung von diabetes | |
| EP4013485A4 (de) | Verfahren und vorrichtungen zur transdermalen neurostimulationsbehandlung | |
| EP4082577A4 (de) | Krebsbehandlungsverfahren und -arzneimittel | |
| EP3995147A4 (de) | Substanz und verfahren zur behandlung von tumoren | |
| EP3746179A4 (de) | Verfahren und zusammensetzungen zur behandlung und vorbeugung von diabetes | |
| EP3616723A4 (de) | Verfahren zur behandlung von myopie und anwendung bei der herstellung eines medikaments | |
| EP3607949A4 (de) | Zusammensetzung zur vorbeugung und behandlung von muskelerkrankungen | |
| EP3609495A4 (de) | Nk1-antagonistenkombination und verfahren zur behandlung von synukleinopathien |